San Francisco—Even as drug costs skyrocketed over the past decade, the total cost of treating pancreatic cancer, adjusted for inflation, has declined. For every additional $1 spent on drugs for pancreatic cancer, nondrug spending fell by $9, according to findings of a new study.
The analysis, conducted by researchers at Virginia Mason Medical Center and the Center for Medicine in the Public Interest (CMPI), showed that average inflation-adjusted, per-patient spending on pancreatic cancer